Prime Medicine Files 2024 Proxy Statement

Ticker: PRME · Form: DEF 14A · Filed: Apr 22, 2025 · CIK: 1894562

Prime Medicine, Inc. DEF 14A Filing Summary
FieldDetail
CompanyPrime Medicine, Inc. (PRME)
Form TypeDEF 14A
Filed DateApr 22, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: proxy-statement, annual-meeting, governance

TL;DR

Prime Medicine dropped its 2024 proxy statement. Get ready for shareholder votes.

AI Summary

Prime Medicine, Inc. filed its definitive proxy statement (DEF 14A) on April 22, 2025, for its fiscal year ending December 31, 2024. The filing, originating from Cambridge, MA, concerns the company's annual meeting and related shareholder matters. Prime Medicine, Inc. is a biotechnology company focused on biological products.

Why It Matters

This filing provides shareholders with essential information regarding the company's governance, executive compensation, and proposals to be voted on at the annual meeting, impacting their investment decisions.

Risk Assessment

Risk Level: low — This is a routine annual filing (DEF 14A) and does not contain new material events or financial disclosures that would inherently increase risk.

Key Players & Entities

  • Prime Medicine, Inc. (company) — Registrant
  • 0001628280-25-018704 (filing_id) — Accession Number
  • 20250422 (date) — Filing Date
  • 20241231 (date) — Fiscal Year End
  • 60 First St. Cambridge, MA 02141 (address) — Business Address

FAQ

What is the purpose of this DEF 14A filing?

This filing is a definitive proxy statement filed by Prime Medicine, Inc. pursuant to Section 14(a) of the Securities Exchange Act of 1934, providing information for its annual shareholder meeting.

When was this proxy statement filed?

The definitive proxy statement was filed on April 22, 2025.

What is Prime Medicine, Inc.'s fiscal year end?

Prime Medicine, Inc.'s fiscal year ends on December 31.

What is the company's primary business according to the filing?

The company's Standard Industrial Classification is 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]'.

Where is Prime Medicine, Inc. located?

The company's business and mailing address is 60 First St., Cambridge, MA 02141.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 22, 2025 regarding Prime Medicine, Inc. (PRME).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.